Sanofi and GSK to provide COVID-19 vaccine doses to COVAX Facility

Sanofi and GlaxoSmithKline have signed a statement of intent with Gavi to provide 200 million doses of their COVID-19 vaccine available to the COVAX Facility. The COVAX Facility is a global risk-sharing mechanism aim at securing COVID-19 vaccines for equitable distribution. The doses of Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine will be used to support COVAX’s ambition to ensure successful shots reach those in need, once they obtain the appropriate approvals. “To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control,” said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur.